Rein Therapeutics (RNTX) Invested Capital (2016 - 2025)
Rein Therapeutics filings provide 10 years of Invested Capital readings, the most recent being $16.9 million for Q4 2025.
- For the quarter ending Q4 2025, Invested Capital fell 68.9% year-over-year to $16.9 million, compared with a TTM value of $16.9 million through Dec 2025, down 68.9%, and an annual FY2025 reading of $16.9 million, down 68.9% over the prior year.
- Invested Capital hit $16.9 million in Q4 2025 for Rein Therapeutics, down from $46.2 million in the prior quarter.
- The five-year high for Invested Capital was $101.0 million in Q2 2024, with the low at $11.2 million in Q3 2023.
- Median Invested Capital over the past 5 years was $47.1 million (2025), compared with a mean of $47.9 million.
- The sharpest move saw Invested Capital soared 750.44% in 2024, then crashed 68.9% in 2025.
- Year by year, Invested Capital stood at $43.9 million in 2021, then crashed by 57.58% to $18.6 million in 2022, then soared by 427.83% to $98.3 million in 2023, then tumbled by 44.67% to $54.4 million in 2024, then tumbled by 68.9% to $16.9 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $16.9 million, $46.2 million, and $48.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.